Lisata Therapeutics to Be Acquired by Kuva Labs

An update from Lisata Therapeutics ( (LSTA) ) is now available.

On March 6, 2026, Lisata Therapeutics agreed to be acquired by privately held Kuva Labs in an all-cash tender offer valuing its common shares at $5.00 each at closing plus one non-tradable contingent value right per share, offering a potential additional $1.00 tied to future regulatory progress for certepetide. The transaction, unanimously recommended by Lisata’s board and expected to close in the second quarter of 2026 subject to a majority tender and other customary conditions, will take Lisata private, delist its stock from Nasdaq and consolidate its oncology-focused pipeline with Kuva’s preclinical NanoMark imaging platform, reshaping incentives for shareholders and aligning future upside with the success of certepetide.

The merger structure includes a second-step merger for untendered shares on identical terms and provides cash and CVR treatment for in-the-money stock options and time-based equity awards, while out-of-the-money options will be canceled without consideration. Termination provisions contemplate a $2 million break fee payable by either side under specified circumstances, and the deal excludes a financing condition, signaling Kuva’s committed funding and adding competitive and execution risk considerations for stakeholders as they evaluate the tender offer.

The most recent analyst rating on (LSTA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.

Spark’s Take on LSTA Stock

According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.

The score is held back primarily by weak financial performance (minimal revenue, large losses, and significant cash burn). Offsetting factors include strong recent technical trend (though overbought), constructive earnings-call progress on expense reductions and runway, and mixed but impactful corporate developments (buyout offer positive, China deal termination negative).

To see Spark’s full report on LSTA stock, click here.

More about Lisata Therapeutics

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing and commercializing innovative therapies for advanced solid tumors and other serious diseases. Its lead cyclic peptide candidate, certepetide, is designed to exploit the company’s CendR Platform technology to enhance targeted delivery and penetration of anti-cancer drugs into solid tumors, and Lisata has already secured commercial and R&D partnerships around this platform.

Average Trading Volume: 165,197

Technical Sentiment Signal: Buy

Current Market Cap: $36.87M

For an in-depth examination of LSTA stock, go to TipRanks’ Overview page.